Special Issue "Engineered Nanoparticle Mediated Vaccine Development for Immunoprevention of Cancer"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 31 December 2022 | Viewed by 293

Special Issue Editors

Dr. Kondareddy Cherukula
E-Mail Website
Guest Editor
Department of Medicine, George Washington University, Washington, DC 20052, USA
Interests: nanoparticles; photothermal therapy; extracellular vesicles; cancer immunotherapies
Special Issues, Collections and Topics in MDPI journals
Dr. Preethi Bala Balakrishnan
E-Mail Website
Co-Guest Editor
Department of Radiology, Stanford University, Stanford, CA 94305-5484, USA
Interests: nano-immunotherapies; nanoparticles; molecular imaging
Dr. Santhosh Kalash Rajendrakumar
E-Mail Website
Co-Guest Editor
Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK
Interests: nanomedicine; cancer immunotherapies; gene therapies

Special Issue Information

Dear Colleagues,

Vaccines are the most efficient tools in defense against malignancies such as cancer and infectious diseases. However, most vaccines suffer from poor immunogenicity, stability, and need for multi-dose vaccine injections to elicit robust and long-lasting immune effects. Recent vaccine developments utilizing nanoparticles (such as lipid nanoparticles) for the global control of the COVID-19 pandemic sparked a renewed interest in these technologies. The use of nanosized particles for vaccine development imparted high immunogenicity, targetability, stability and sustained/controlled release properties that enhance the host’s immune response.

Several nanoparticulate systems such as liposomes, polymers, micelles, virus like nanoparticles, and inorganic nanoparticles, to name a few, have been utilized for cancer vaccination strategies. Several factors such as size, shape, surface charge, route of administration, time in circulation, etc., of these nano-constructs determines the efficacy of the loaded immunological agents (vaccines). Cancer malignancies differ widely from each other in tumor antigen type and tumor microenvironment, which includes tumor resident and infiltrating immune cells. They are highly heterogenous within the same type of cancer (immune “hot” or “cold” tumors). For this reason, one-for-all design in the nanoparticle development to positively trigger immunogenicity will not work effectively for all types of cancer. A precise engineering of these systems by taking the tumor microenvironment and its immune status into consideration is of utmost importance. Engineering of nanoparticle design parameters will bring out a stable functional nanoplatform for cancer vaccine delivery.

This Special Issue, titled ‘Engineered Nanoparticle Mediated Vaccine Development for Immunoprevention of Cancer’, will aim to bring the reader’s attention to the innovative engineering strategies of nanoparticle systems to improve cancer vaccine delivery and efficacy.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  1. Engineering of nanoparticulate systems for efficient delivery of cancer vaccines;
  2. Immunomodulating nanoparticles design and validation;
  3. Nanoparticles design for enhanced targeted delivery;
  4. Nanoparticle system as an efficient cancer adjuvant;
  5. Design and validation of theranostic nanoparticles for cancer diagnosis and prevention.

We look forward to receiving your contributions.

Dr. Kondareddy Cherukula
Dr. Preethi Bala Balakrishnan
Dr. Santhosh Kalash Rajendrakumar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • nanoparticles
  • vaccines
  • nanotechnology
  • immune cell targeting
  • adjuvant
  • antigen
  • engineered nanoparticles

Published Papers

This special issue is now open for submission.
Back to TopTop